Please login to the form below

Not currently logged in
Email:
Password:

HS

This page shows the latest HS news and features for those working in and with pharma, biotech and healthcare.

Lucid picks up rare disease and orphan drugs trophy at PMEA 2017

Lucid picks up rare disease and orphan drugs trophy at PMEA 2017

The agency’s ‘EIDON’project for AbbVie developed a specialist network and increased the number of specialist centres to advance outcomes of patients with hidradenitis suppurativa (HS).

Latest news

  • AbbVie's 'The Story of HS' wins at PMEA 2016 AbbVie's 'The Story of HS' wins at PMEA 2016

    AbbVie's 'The Story of HS' wins at PMEA 2016. Takes top prize in Excellence in Training Capability Development. ... UK. Supported by TVF Communications, AbbVie created 'The Story of HS: A Patient Journey' to provide educational information based on

  • AbbVie launches chronic skin disease awareness campaign AbbVie launches chronic skin disease awareness campaign

    On average, an accurate diagnosis for someone who suffers from HS is over eight years, according to the pharma firm. ... Tools including a symptom checker and a printable guide for discussing HS with dermatologists are available on the website.

  • Finalists revealed for Communiqué Awards 2016 Finalists revealed for Communiqué Awards 2016

    by Tonic. for Eisai. HS patient pathway eLearning programme. by TVF Communications.

  • AbbVie's Humira wins ninth US approval AbbVie's Humira wins ninth US approval

    Hidradenitis suppuritiva (HS) is a chronic inflammatory skin disease typically characterised by lesions around armpits, groin, on the buttocks or under the breasts. ... Adalimumab significantly reduced the signs of HS in clinical trials, and this FDA

  • Humira gains EU licence first for Hidradenitis Suppurativa Humira gains EU licence first for Hidradenitis Suppurativa

    Specifically, Humira can now be used in patients with moderate to severe Hidradenitis Suppurativa (HS) - and marks the first therapy ever to be approved for the disease. ... Patients with HS can experience immense pain and the condition often

More from news
Approximately 1 fully matching, plus 8 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics